MRI in breast cancer therapy monitoring

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 712-720

  Mclaughlin, Rebekah ^a,b   Hylton, Nola ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1H MRS; Breast cancer; Diffusion weighted imaging; Dynamic contrast enhanced imaging; MRI; Neoadjuvant chemotherapy; Treatment monitoring

Indexed keywords

1H MRS; BREAST CANCER; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST-ENHANCED IMAGING; NEOADJUVANT CHEMOTHERAPY; TREATMENT MONITORING;

CHEMOTHERAPY; DIAGNOSIS; DISEASE CONTROL; IMAGING TECHNIQUES; MAMMOGRAPHY; MONITORING; PATIENT TREATMENT; RADIOLOGY; SURFACE DIFFUSION; ULTRASONIC APPLICATIONS;

DISEASES;

ANTINEOPLASTIC AGENT; CHOLINE; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; DOXORUBICIN; GADOLINIUM;

APPARENT DIFFUSION COEFFICIENT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MONITORING; DYNAMIC CONTRAST ENHANCEMENT; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERSONALIZED MEDICINE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; TREATMENT RESPONSE; TUMOR VOLUME; VOXEL BASED MORPHOMETRY;

BREAST NEOPLASMS; DRUG MONITORING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 79960836136     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1739     Document Type: Review

References (76)

1. Boetes C, Mus RD, Holland R, Barentsz JO, Strijk SP, Wobbes T, Hendriks JH, Ruys SH. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology, 1995; 197: 743-747.
2. Harms SE, Flamig DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, Savino DA, Wells RV. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology, 1993; 187: 493-501.
3. Soderstrom CE, Harms SE, Copit DS, Evans WP, Savino DA, Krakos PA, Farrell RS, Flamig DP. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. Radiology, 1996; 201: 427-432.
4. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J. Clin. Oncol. 1999; 17: 110-119.
5. Weatherall P, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J. Magn. Reson. Imaging, 2001; 13: 868-875.
6. Drew PJ, Kerin MJ, Mahapatra T, Malone C, Monson JRT, Turnbull LW, Fox JN. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur. J. Surg. Oncol. 2001; 27: 617-620.
7. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res. Treat. 2002; 72: 145-152.
8. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, Samulski TV, Dewhirst MW. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am. J. Roentgenol. 2003; 181: 1275-1282.
9. Thibault F, Nos C, Meunier M, ElKhoury C, Ollivier L, Sigal-Zafrani B, Clough K. MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. Am. J. Roentgenol. 2004; 183: 1159-1168.
10. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur. Radiol. 2004; 14: 1371-1379.
11. Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi M, Bersiga A, Generali D, Volpi D, Marini U, Aguggini S, Tampellini M, Alquati P, Olivetti L, Dogliotti L. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res. Treat. 2004; 85: 211-218.
12. Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am. J. Roentgenol. 2005; 184: 868-877.
13. Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ, Ueda S, Yanagisawa T, Sato Y, Tamura S, Noguchi S. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006; 12: 130-137.
14. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J. Surg. Oncol. 2007; 96: 474-480.
15. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer, 2008; 98: 289-293.
16. Esteva FJ, Hortobagyi GN. Integration of systemic chemotherapy in the management of primary breast cancer. Oncologist, 1998; 3: 300-313.
17. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz JAB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 1998; 16: 2672-2685.
18. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J. Natl. Cancer Inst. Monogr. 2001; 30: 96-102.
19. Schegerin M, Tosteson A, Kaufman P, Paulsen K, Pogue B. Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective. Breast Cancer Res. Treat. 2009; 114: 537-547.
20. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am. J. Roentgenol. 2002; 179: 1193-1199.
21. Cheung YC, Chen SC, Su MY, See LC, Hsueh S, Chang HK, Lin YC, Tsai CS. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res. Treat. 2003; 78: 51-58.
22. Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin. Radiol. 2006; 61: 946-953.
23. Kim HJ, Im YH, Han BK, Choi N, Lee J, Kim JH, Choi YL, Ahn JS, Nam SJ, Park YS, Choe YH, Ko YH, Yang JH. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol. 2007; 46: 996-1003.
24. Chou CP, Wu MT, Chang HT, Lo YS, Pan HB, Degani H, Furman-Haran E. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad. Radiol. 2007; 14: 561-573.
25. Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. Am. J. Roentgenol. 2008; 190: 1630-1636.
26. Chen JH, Feig B, Hsiang DJB, Butler JA, Mehta RS, Bahri S, Nalcioglu O, Su MY. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann. Surg. 2009; 249: 448-454.
27. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, Regge D, Aglietta M. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res. Treat. 2004; 83: 67-76.
28. Lorenzon M, Zuiani C, Londero V, Linda A, Furlan A, Bazzocchi M. Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool? Eur. J. Radiol. 2009; 71: 82-88.
29. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 2002; 12: 1711-1719.
30. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112: 17-26.
31. Straver ME, Loo CE, Rutgers EJ, Oldenburg HS, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann. Surg. 2010; 251: 701-707.
32. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer, 1981; 47: 207-214.
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000; 92: 205-216.
34. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging-pilot study. Radiology, 2003; 228: 63-69.
35. Chang YC, Huang CS, Liu YJ, Chen JH, Lu YS, Tseng WYI. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys. Med. Biol. 2004; 49: 3593-3602.
36. Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, Baker LH. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2005; 92: 231-238.
37. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2005; 91: 1-10.
38. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Am. J. Roentgenol. 2005; 184: 1774-1781.
39. Armitage P, Behrenbruch C, Brady M, Moore N. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med. Image Anal. 2005; 9: 315-329.
40. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br. J. Cancer, 2006; 94: 427-435.
41. Kumar M, Jagannathan N, Seenu V, Dwivedi S, Julka P, Rath G. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J. Magn. Reson. Imaging, 2006; 24: 325-332.
42. Tan PC, Pickles MD, Lowry M, Manton DJ, Turnbull LW. Lesion T2 relaxation times and volumes predict the response of malignant breast lesions to neoadjuvant chemotherapy. Magn. Reson. Imaging, 2008; 26: 26-34.
43. Sharma U, Danishad KKA, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009; 22: 104-113.
44. Johansen R, Jensen LR, Rydland J, Goa PE, Kvistad KA, Bathen TF, Axelson DE, Lundgren S, Gribbestad IS. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J. Magn. Reson. Imaging, 2009; 29: 1300-1307.
45. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J. Clin. Oncol. 2001; 19: 4224-4237.
46. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. 2005; 97: 188-194.
47. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 1999; 17: 460-469.
48. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. The Breast, 2003; 12: 320-327.
49. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn. Reson. Imaging, 2006; 24: 843-847.
50. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology, 2006; 239: 361-374.
51. Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J. Magn. Reson. Imaging, 2007; 26: 615-623.
52. Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters MJV, Gilhuijs KGA. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. Am. J. Roentgenol. 2008; 191: 1331-1338.
53. Ah-See MLW, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 2008; 14: 6580-6589.
54. Bahri S, Chen JH, Mehta R, Carpenter P, Nie K, Kwon SY, Yu H, Nalcioglu O, Su MY. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann. Surg. Oncol. 2009; 16: 1619-1628.
55. 1H MR spectroscopy. Radiology, 2009; 251: 653-662.
56. American College of Radiology (ACR) BI-RADS - magnetic resonance imaging. In: Breast Imaging Reporting and Data System (BI-RADS) Breast Imaging Atlas, 4th edn. American College of Radiology: Reston, VA; 2003.
57. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann. Surg. Oncol. 2001; 8: 549-559.
58. Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Kobrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. Magnetic resonance imaging of the breast prior to biopsy. J. Am. Med. Assoc. 2004; 292: 2735-2742.
59. Wasser K, Sinn H, Fink C, Klein S, Junkermann H, Lãijdemann H, Zuna I, Delorme S. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur. Radiol. 2003; 13: 1213-1223.
60. Wasser K, Klein S, Fink C, Junkermann H, Sinn H, Zuna I, Knopp M, Delorme S. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur. Radiol. 2003; 13: 80-87.
61. Khoury CE, Servois V, Thibault F, Tardivon A, Ollivier L, Meunier M, Allonier C, Neuenschwander S. MR quantification of the washout changes in breast tumors under preoperative chemotherapy: feasibility and preliminary results. Am. J. Roentgenol. 2005; 184: 1499-1504.
62. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn. Reson. Imaging, 2007; 25: 1-13.
63. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging, 1997; 7: 91-101.
64. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging, 1999; 10: 223-232.
65. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia, 1999; 1: 113-117.
66. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0T. Radiology, 2005; 236: 465-475.
67. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell. Biochem. 2003; 90: 525-533.
68. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer, 2001; 84: 1016-1022.
69. 1H MR spectroscopy-a pilot study at 4T. Radiology, 2004; 233: 424-431.
70. Danishad KKA, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed. 2010; 23: 233-241.
71. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J. Magn. Reson. Imaging, 2004; 19: 68-75.
72. Baek HM, Chen JH, Yu HJ, Mehta R, Nalcioglu O, Su MY. Detection of choline signal in human breast lesions with chemical-shift imaging. J. Magn. Reson. Imaging, 2008; 27: 1114-1121.
73. 1H MR spectroscopy. Magn. Reson. Med. 2003; 50: 1134-1143.
74. 1H MR spectroscopy using water as an internal reference at 1.5T. Magn. Reson. Mater. Phys. 2006; 19: 96-104.
75. 1H MRS of breast lesions. Magn. Reson. Med. 2002; 48: 215-222.
76. Jagannathan N, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK. Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed. 1998; 11: 414-422.